Recent research from Houston Methodist Hospital showed that a new immunotherapy was safe for patients with ALS and also revealed surprising results that could bring hope to patients who have this relentlessly progressive and fatal disease
Amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig's disease, is a nervous system disorder in which nerve cells that control muscle movement degenerate, leading to weakness, speech and swallowing difficulties, impaired breathing, and ultimately death.
Researchers focused on regulatory T cells, also known as Tregs, which are immune cells that help protect the body from harmful inflammation that accelerates the progression of ALS.
"We found that many of our ALS patients not only had low levels of Tregs but also that their Tregs were not functioning properly," said Appel, senior author, and chair of the department of neurology at Houston Methodist Hospital. "We believed that improving the number and function of Tregs in these patients would affect how their disease progressed."
Three patients at different stages of ALS progression for the study
"As we believed, our results showed it was safe to increase their Treg levels," Appel said. "What surprised us was that the progression of their ALS dramatically slowed while they received infusions of properly functioning Tregs. My hope is that this research changes ALS from a death sentence to a life sentence. It won't cure a patient's disease, but we can make a difference."
The three patients in this study underwent leukapheresis, a procedure where blood is removed, white blood cells are separated from red blood cells, and red blood cells are returned to the body. Tregs were then separated from the white blood cells.
Appel's research team found Tregs that were not functioning properly in ALS patients returned to normal once outside of the body. They collaborated with M.D. Anderson Cancer Center's Stem Cell Transplantation and Cellular Therapy program to increase the number of each patient's own Tregs before administering them intravenously back into the patients.
Each patient received eight Treg infusions during the study. The first four infusions were administered every two weeks, and the last four were administered once a month.
progression was measured using two ALS progression rating scales. Between the first round and second round of Treg infusions and then after the second round of infusions was completed, progression resumed within a few weeks to months following the last Treg infusion.
"A person has approximately 150 million Tregs circulating in their blood at any given time," Thonhoff said. "Each dose of Tregs given to the patients in this study resulted in about a 30 to 40 percent increase over normal levels. Slowing of disease progression was observed during each round of four Treg infusions."
Next, Appel and Thonhoff will launch a Phase 2 study to further evaluate the safety and effectiveness of Treg infusions in slowing the progression of ALS. They hope to turn this research into an off-the-shelf cellular therapy for ALS patients.